A Proof-of-Concept, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of FST-100 Ophthalmic Suspension in the Treatment of Acute Adenoviral Conjunctivitis

Trial Profile

A Proof-of-Concept, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of FST-100 Ophthalmic Suspension in the Treatment of Acute Adenoviral Conjunctivitis

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Povidone iodine/dexamethasone (Primary)
  • Indications Adenovirus infections; Infectious conjunctivitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Foresight Biotherapeutics
  • Most Recent Events

    • 24 Apr 2017 Primary endpoint (Adenoviral eradication and clinical resolution of the infection) has been met, according to a Shire media release.
    • 24 Apr 2017 Results published in a Shire media release.
    • 28 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top